Secukinumab: A positive outcome in a patient with severe psoriasis and HBV-HCV co-infection

Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicentre cohort study of 37 patients and review of the literature

(2017) S. Piaserico et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis

(2017) P. Gisondi et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Management of psoriasis patients with hepatitis B or hepatitis C virus infection

(2016) Claudio Bonifati et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Are Anti-TNF-α Agents Safe for Treating Psoriasis in Hepatitis C Virus Patients with Advanced Liver Disease? Case Reports and Review of the Literature

(2015) Sergio Di Nuzzo et al.   DERMATOLOGY

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis

(2014) Filomena Morisco et al.   BMC GASTROENTEROLOGY

From the Medical Board of the National Psoriasis Foundation: Recommendations for screening for hepatitis B infection prior to initiating anti–tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis

(2013) Kiran Motaparthi et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

(2012) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs

(2012) Jing Tan et al.   CLINICAL RHEUMATOLOGY